SCHEMBL8608558

SCHEMBL8608558

CC1(C)COC(c2ccccc2)OC1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.69
KMT2A Q03164 2/20 0.69
CYP2C19 P33261 1/20 0.69
SMN1; SMN2 Q16637 2/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
KCNA4 P22459 1/20 0.51
KCNA1 Q09470 1/20 0.51
KCNAB1 Q14722 1/20 0.51
SOAT1 P35610 1/20 0.47
MAPK1 P28482 1/20 0.46
MAPT P10636 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
TSHR P16473 1/20 0.43
KDM1A O60341 4/20 0.42
MAOA P21397 4/20 0.42
MAOB P27338 4/20 0.42
BRD4 O60885 1/20 0.41
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18119744 0.89 SMN1; SMN2 (0.62) MEN1KMT2ACYP2C19SMN1; SMN2NPC1
SCHEMBL15890432 0.88 MEN1 (0.55) MEN1KMT2ACYP2C19SMN1; SMN2NPC1
SCHEMBL13701306 0.84 MEN1 (0.50) MEN1KMT2ACYP2C19SMN1; SMN2NPC1
SCHEMBL18119746 0.83 SMN1; SMN2 (0.57) MEN1KMT2ACYP2C19SMN1; SMN2NPC1
SCHEMBL764123 0.82 CYP2C19 (1.00) MEN1KMT2ACYP2C19SMN1; SMN2NPC1
SCHEMBL22160331 0.81 SMN1; SMN2 (0.64) MEN1KMT2ACYP2C19SMN1; SMN2NPC1
SCHEMBL11460056 0.81 SMN1; SMN2 (0.56) MEN1KMT2ACYP2C19SMN1; SMN2NPC1
SCHEMBL9876533 0.80 MEN1 (0.60) MEN1KMT2ACYP2C19SMN1; SMN2NPC1
SCHEMBL18119745 0.80 SMN1; SMN2 (0.54) MEN1KMT2ACYP2C19SMN1; SMN2NPC1
SCHEMBL9778599 0.80 RAB9A (0.48) MEN1KMT2ACYP2C19SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5686621-A Substituted hydrindanes for the treatment of angiogenesis-dependent diseases ALCON LABORATORIES, INC. (US) 1997-11-11 US claimed
WO-1994004143-A1 SUBSTITUTED HYDRINDANES FOR THE TREATMENT OF ANGIOGENESIS-DEPENDENT DISEASES ALCON LABORATORIES, INC. (US) 1994-03-03 WO claimed
US-4304921-A Method of preparing β-halo esters from cyclic acetals VANDERBILT UNIVERSITY (US) 1981-12-08 US claimed
EP-2939997-B1 POLYETHER DIOL AND METHOD FOR PRODUCING THE SAME MITSUBISHI GAS CHEMICAL CO (JP) 2018-12-05 EP disclosed
CN-104884418-B Polyether diol and process for producing the same 三菱瓦斯化学株式会社 2017-12-01 CN disclosed
US-9790155-B2 Polyether diol and method for producing the same MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2017-10-17 US disclosed
US-20150329454-A1 POLYETHER DIOL AND METHOD FOR PRODUCING THE SAME MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2015-11-19 US disclosed
EP-2939997-A1 POLYETHER DIOL AND METHOD FOR PRODUCING THE SAME Mitsubishi Gas Chemical Company, Inc. (JP) 2015-11-04 EP disclosed
US-8962721-B2 Nucleating agents for polyolefins based on acetal compounds RELIANCE INDUSTRIES LIMITED (IN) 2015-02-24 US disclosed
US-20130116366-A1 NOVEL NUCLEATING AGENTS FOR POLYOLEFINS BASED ON ACETAL COMPOUNDS RELIANCE INDUSTRIES LIMITED (IN) 2013-05-09 US disclosed
US-20120149693-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-06-14 US disclosed
US-5780687-A REACTING 1,3-DIOXANES WITH HYDROGEN IN PRESENCE OF HYDROGENATION CATALYST HOECHST AKTIENGESELLSCHAFT (DE) 1998-07-14 US disclosed
EP-0810202-A2 Process for the preparation of 4-oxaamines HOECHST AKTIENGESELLSCHAFT (DE) 1997-12-03 EP disclosed
EP-0810194-A1 Process for preparing 3-oxyalkylpropan-1-ols HOECHST AKTIENGESELLSCHAFT (DE) 1997-12-03 EP disclosed
US-5686621-A Substituted hydrindanes for the treatment of angiogenesis-dependent diseases ALCON LABORATORIES, INC. (US) 1997-11-11 US disclosed
US-5464866-A Substituted hydrindanes for the treatment of angiogenesis-dependent diseases ALCON LABORATORIES, INC. (US) 1995-11-07 US disclosed
WO-1994004143-A1 SUBSTITUTED HYDRINDANES FOR THE TREATMENT OF ANGIOGENESIS-DEPENDENT DISEASES ALCON LABORATORIES, INC. (US) 1994-03-03 WO disclosed
EP-0199210-B1 CONVERSION OF 1,3-DIOXANES INTO 4-OXA-ALDEHYDES BASF Aktiengesellschaft (DE) 1991-10-16 EP disclosed
US-4324921-A CATALYTIC ISOMERIZATION OF 5,5-DIMETHYL-1,3-DIOXANS HOECHST AKTIENGESELLSCHAFT (DE) 1982-04-13 US disclosed
US-4198323-A 2,2,5-Trimethyl-5-phenyl-1,3-dioxane and perfume compositions containing it HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) 1980-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149693-A1 THERAPEUTIC COMPOUNDS HTR2C, GRK2, GRK3 MEN1 4590/4885KMT2A 4328/4885CYP2C19 3767/4885
US-20150329454-A1 POLYETHER DIOL AND METHOD FOR PRODUCING THE SAME DHCR7, HSD17B7, HSD17B12 MEN1 1319/4885KMT2A 1683/4885CYP2C19 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.